PEP-DSIP • RESEARCH USE ONLY

DSIP

DSIP (Delta Sleep–Inducing Peptide) is a neuropeptide that supports deep, restorative sleep and nervous-system regulation. It helps calm stress responses, supports natural sleep architecture, and promotes hormonal balance associated with high-quality rest.

8 mg

Per Bottle

— 50 mcg per spray

>99%

Purity

— Third-party verified

160

Sprays per bottle

Protocol & Dosing

Use once daily, 15–30 minutes before bedtime. For individuals with severe insomnia, high stress, or difficulty winding down, dosing may be taken 30–60 minutes before bed to allow gradual relaxation. DSIP is gentle and suitable for repeated nightly use, but brief cycling helps maintain sensitivity.

Standard

100 mcg (2 sprays)

Medium

200 mcg (4 sprays)

Higher

300 mcg (6 sprays)

Cycles

May be used nightly for 8–12 weeks
Take 1 week off every 8–12 weeks to maintain sensitivity and avoid tolerance

Key Benefits

Promotes deeper and more restorative sleep, reduces stress and nighttime cortisol, supports relaxation and sleep onset, enhances sleep quality, and supports overall hormonal and nervous-system balance.

Guidance

Start with 2 sprays nightly
Increase gradually only if needed
Use once nightly only (do not redose during the night)
Do not exceed 6 sprays per night unless directed
Ideal for sleep onset, sleep depth, and stress-related insomnia
Non-sedating and non-habit forming
Can be combined with Epitalon or Selank for enhanced circadian and relaxation support (use lower doses when stacking)

PROPRIETARY DELIVERY TECHNOLOGY

Protixa ION System™

Nasal delivery is facilitated with the Protixa ION System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange

Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.

Dual-polarity solubilization

Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.

Keratin modulation & partitioning

Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).

Superior loading vs. lipid carriers

Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Protixa ION System reaches therapeutically relevant layers.

>57× vs. saline · <10 nm (DLS)

>57× barrier penetration vs. saline in an ex vivo epithelial model (Protixa third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.

Safety, stability & distribution

ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Nasal peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117

Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA